Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors
The Journal of Pathology · 2026
DOI: 10.1002/path.70063 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, 2026. Verfasst von Ying Yang und 29 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medic…. Hauptthemen laut MEDLINE: Interleukin-13 Receptor alpha2 Subunit, Induced Pluripotent Stem Cells, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Chongqing Municipal Science and Technology Bureau, National Natural Science Foundation of China, Chongqing Municipal Health Commission.
Abstract (Originalsprache)
Macrophages exhibit extensive tumor infiltration capacity across diverse solid malignancies, establishing macrophage‐targeted immunotherapies as an emerging frontier in oncology. Genetic engineering of macrophages using chimeric antigen receptor (CAR) technology − enabling recognition and phagocytosis of neoplastic cells − is emerging as a potential therapeutic strategy against solid tumors. Human induced pluripotent stem cells (iPSCs) provide a renewable platform for the efficient differentiation of functionally competent macrophages. In this study, we engineered human iPSC‐derived CAR macrophages (iCAR‐M) targeting interleukin‐13 receptor subunit alpha 2 (IL‐13Rα2). Pan‐tumor transcriptomic and immunohistochemical analyses revealed that IL‐13Rα2, a tumor‐associated antigen, was overexpressed in human glioblastoma (GBM), uterine carcinosarcoma (UCS), and melanoma specimens. In vitro phagocytosis assays revealed target‐specific clearance of IL‐13Rα2‐positive tumor cells by iCAR‐M. Intracranial administration of iCAR‐M potently suppressed tumor growth, enhanced intratumoral cytotoxic T‐cell infiltration, and prolonged the survival of humanized, immunocompetent mice bearing GBM xenografts. The administered iCAR‐M maintained phagocytic capacity in vivo and acquired an M1‐like pro‐inflammatory phenotype. Comprehensive safety assessment revealed no detectable evidence of systemic toxicity or treatment‐related neurotoxicity. Collectively, these results demonstrate the potent efficacy and favorable safety profile of iPSC‐derived, IL‐13Rα2‐targeted CAR macrophages, supporting their therapeutic potential against solid tumors. © 2026 The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laborat…
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Department of Blood Transfusion, the First Affiliated Hospital (Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, PR China.
- Department of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of PR China, Guangzhou, PR China.
- School of Medicine, Chongqing University, Chongqing, PR China.
- Chongqing Yuyue Scientific Research Center for Pathology, Chongqing Institute of Advanced Pathology, Jinfeng Laboratory, Chongqing, PR China.
ORCID-Profile: Yi-Fang Ping, Xiu-Wu Bian, Yu Shi
Förderung
- Chongqing Municipal Science and Technology Bureau
- National Natural Science Foundation of China
- Chongqing Municipal Health Commission
- National Key Research and Development Program of China
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Yang, Y., Wang, L., Zhang, Y., Lyu, S., Ruan, Q., Wang, C., Dou, F., Liang, G., Yan, G., Wang, M., Fan, H., Qi, H., Kong, W., Guo, H., Liu, Q., Wang, W., Mao, M., Huang, Y., Zhou, X., …, & Shi, Y. (2026). Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors. The Journal of Pathology. https://doi.org/10.1002/path.70063
Vancouver
Yang Y, Wang L, Zhang Y, Lyu S, Ruan Q, Wang C, et al. Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors. The Journal of Pathology. 2026. doi:10.1002/path.70063
BibTeX
@article{Yang2026,
author = {Yang, Ying and Wang, Lujing and Zhang, Yi and Lyu, Shuzhen and Ruan, Qianying and Wang, Chao and Dou, Feiyue and Liang, Gongbo and Yan, Guangning and Wang, Mengru and Fan, Haizhen and Qi, Haoyue and Kong, Weikai and Guo, Haitao and Liu, Qing and Wang, Wenying and Mao, Min and Huang, Yuxi and Zhou, Xinyue and Duan, Jiayu and Song, Wangyang and Huang, Bangguo and Cheng, Yuhui and Zhou, Lei and Xu, Senlin and Shen, Jun and Ping, Yi-Fang and Bian, Xiu-Wu and He, Zhicheng and Shi, Yu},
title = {Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors},
journal = {The Journal of Pathology},
year = {2026},
doi = {10.1002/path.70063}
}
EUVIMED